IBD & Intestinal Disorders
Member Spotlight
Advancing personalized medicine in IBD
Joanna Melia, MD, is dedicated to advancing the field of personalized medicine for patients with IBD.
News
FDA approves mirikizumab for ulcerative colitis
It’s the first IL-23 inhibitor to be approved in the United States for UC.
Conference Coverage
RSV more common in IBD
Study details higher rates of RSV in patients with IBD, plus cases are more serious.
Conference Coverage
New study ties ultra-processed foods to IBD
Adults who consumed diets rich in ultra-processed foods were shown to have an elevated relative risk for IBD, Crohn’s disease, and ulcerative...
News from the FDA/CDC
FDA approves subcutaneous infliximab for IBD
The new formulation was approved based on phase 3 pivotal trials that evaluated the safety and efficacy of infliximab-dyyb as maintenance therapy...
From the AGA Journals
Two-thirds with microscopic colitis respond to bile acid sequestrants
Treatment may resolve chronic diarrhea in some patients with microscopic colitis.
From the AGA Journals
Low-certainty evidence supports probiotics for IBS
Some combinations of probiotics or strains may be beneficial in IBS, but the evidence for efficacy is poor.
News from the FDA/CDC
FDA OKs subcutaneous vedolizumab for UC maintenance therapy
The safety profile of subcutaneous vedolizumab was “generally consistent” with the intravenous form of the drug, with the addition of injection-...
From the Journals
ChatGPT may aid decision-making in the ED for acute ulcerative colitis
Chatbot provided a detailed answer depicting severity of every variable of the criteria and an overall severity classification.
From the Journals
Many young people stop ulcerative colitis maintenance treatment, risking relapse
Globally, the incidence of UC is increasing fastest in younger populations. It’s estimated that up to 30% of individuals with UC are diagnosed in...